25389-98-4

Basic information

• Product Name: Neomycin B sulfate
• CAS NO: 25389-98-4
• Molecular Formula: C₂₃H₄₆N₆O₁₃*3H₂O₄S
• Molecular Weight: 908.879
• Mol File: 25389-98-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 927.1°Cat760mmHg
• Flash Point: 514.5°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0mmHg at 25°C
• CAS DataBase Reference: Neomycin B sulfate(CAS DataBase Reference)
• NIST Chemistry Reference: Neomycin B sulfate(25389-98-4)
• EPA Substance Registry System: Neomycin B sulfate(25389-98-4)

Safety Data

• Hazardous Substances Data: 25389-98-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C23H46N6O13.H2O4S/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22;1-5(2,3)4/h5-23,30-36H,1-4,24-29H2;(H2,1,2,3,4)

Downstream Products

• 468065-21-6 hexaazidoneomycin B 
• 241820-92-8 hexa-N-Boc neomycin B 
• 15446-43-2 neamine tetrahydrochloride 
• 41547-94-8 4-O-(2,6-di-deoxy-α-D-2,6-di-amine-glucopyranosyl)-2-deoxy-streptamine hydrochloride 
• 58096-78-9 Hexa-N-(benzyloxycarbonyl)neomycin B 
• 2037-48-1 2-deoxystreptamine 
• 90899-14-2 (1α,2β,3α,4β,6β)-4,6-Diazido-1,2,3-cyclohexantriol 
• 1393446-89-3 C₂₅H₄₈N₆O₁₄ 
• 3947-65-7 neomycin A 
• 119-04-0 neomycin B 

Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

Oral delivery systems for microparticles

PCT No. PCT/AU92/00141 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Apr. 2, 1992 PCT Pub. No. WO92/17167 PCT Pub. Date Oct. 15, 1992There are disclosed complexes and compositions for oral delivery of a substance or substances to the circulation or lymphatic drainage system of a host. The complexes of the invention comprise a microparticle coupled to at least one carrier, the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host, and the microparticle entrapping or encapsulating, or being capable of entrapping or encapsulating, the substance(s). Examples of suitable carriers are mucosal binding proteins, bacterial adhesins, viral adhesins, toxin binding subunits, lectins, Vitamin B12 and analogues or derivatives of Vitamin B12 possessing binding activity to Castle's intrinsic factor.